Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Biohaven Pharmaceutical Holding Company Ltd. (BHVN)

19.17   0.35 (1.86%) 02-02 16:00
Open: 19.19 Pre. Close: 18.82
High: 20.57 Low: 18.36
Volume: 1,470,084 Market Cap: 1,307(M)

Technical analysis

as of: 2023-02-02 4:29:08 PM
Overall:       
Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 24.02     One year: 28.06
Support: Support1: 15.52    Support2: 12.4
Resistance: Resistance1: 20.56    Resistance2: 24.02
Pivot: 18.45
Moving Average: MA(5): 18.89     MA(20): 17.63
MA(100): 26.75     MA(250): 90.83
MACD: MACD(12,26): 0.9     Signal(9): 0.8
Stochastic oscillator: %K(14,3): 74.6     %D(3): 76.5
RSI: RSI(14): 60.7
52-week: High: 151.5  Low: 5.53
Average Vol(K): 3-Month: 1,106 (K)  10-Days: 917 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ BHVN ] has closed below upper band by 24.6%. Bollinger Bands are 92.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 76 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 20.59 - 20.69 20.69 - 20.78
Low: 18.14 - 18.25 18.25 - 18.34
Close: 19.01 - 19.18 19.18 - 19.32

Company Description

Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavegepant that is in phase III clinical trials for acute and preventive treatment of migraine, as well as respiratory complications and non-migraine studies; and BHV-3100 for non-migraine indications. The company also offers Troriluzole for spinocerebellar ataxia and obsessive compulsive disorders, as well as Alzheimer diseases; BHV-0223, a product for amyotrophic lateral sclerosis; BHV-5000/5500 for neuropsychiatric indications; and Verdiperstat, a product for multiple system atrophy and amyotrophic lateral sclerosis. Biohaven Pharmaceutical Holding Company Ltd. has a collaboration agreement with Cove to facilitate telemedicine evaluation for migraine sufferers. The company was incorporated in 2013 and is headquartered in New Haven, Connecticut.

Headline News

Thu, 02 Feb 2023
BHVN Stock: What's Next For Biohaven After A $12 Billion Buyout ... - Investor's Business Daily

Wed, 01 Feb 2023
Mumbai: Car catches fire near Shiv Sena Bhavan; no casualties reported - Mumbai Live

Tue, 31 Jan 2023
Russell Investments Group Ltd. Reduces Holdings in Biohaven Ltd ... - MarketBeat

Mon, 30 Jan 2023
The truth of special screening of ‘Pathaan’ at Rashrapati Bhavan, which wasn’t special at all: Details - OpIndia

Mon, 30 Jan 2023
How ‘Mughal Gardens’ Became ‘Amrit Udyan’: Rashtrapati Bhavan Website Tells a Shoddy Story - The Wire

Fri, 27 Jan 2023
Truist Financial Corp reduces its stake in Biohaven Ltd. (NYSE:BHVN) - Best Stocks

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NYSE
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 68 (M)
Shares Float 54 (M)
% Held by Insiders 14.6 (%)
% Held by Institutions 38.1 (%)
Shares Short 4,630 (K)
Shares Short P.Month 2,530 (K)

Stock Financials

EPS -11.86
EPS Est Next Qtl -1.12
EPS Est This Year -5.45
EPS Est Next Year -4.39
Book Value (p.s.) 1.47
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) 0
Return on Equity (ttm) 0
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -5.93
Qtrly Earnings Growth 0
Operating Cash Flow -255 (M)
Levered Free Cash Flow 0 (M)

Stock Valuations

PE Ratio -1.62
PEG Ratio 0
Price to Book value 13.04
Price to Sales 0
Price to Cash Flow -5.12

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.